The effect of montelukast on atherogenesis in APOE-LDLR-double knockout mice

• Autorzy: Jawien J. , Gajda M. , Wolkow P. , Zuranska J. , Olszanecki R. , Korbut R.
• Języki publikacji: EN

Abstrakty

EN

We have shown that inhibitors of five lipoxygenase activating protein (FLAP) - MK-886 and BAYx1005 inhibit atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, investigated whether cysteinyl leukotrienes receptor inhibitor - montelukast, given at a dose of 0.125 µg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model montelukast significantly decreased atherogenesis, measured both by "en face" method (25.5±2.% vs. 17.23 ± 1.8%) and "cross-section" method (455 494 ± 26 477 µm2 vs. 299 201 ± 20 373 µm2). The results were, however, less pronounced, comparing to FLAP inhibitors. This is the first report showing the effect of montelukast on atherogenesis in gene-targeted mice.

Słowa kluczowe

EN

lipoxygenase activity; atherogenesis; atherosclerosis; mouse; apolipoprotein E; mice; knockout mouse; knockout mice; cysteinyl leukotriene; inflammatory disease; LDL receptor

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2008
• Tom: 59
• Numer: 3
• Opis fizyczny: p.633-639,fig.,ref.

Twórcy

autor

Jawien J.

• Jagiellonian University School of Medicine, Grzegorzecka Str.16, 31-531 Krakow, Poland

autor

Gajda M.

autor

Wolkow P.

autor

Zuranska J.

autor

Olszanecki R.

autor

Korbut R.